Natural Product (NP) Details
General Information of the NP (ID: NP1644) | |||||
---|---|---|---|---|---|
Name |
Vincristine
|
||||
Synonyms |
LCR; Leurocristine; Marqibo; Oncovine; Tecnocris; VCR; VIN; Vincasar; Vincristina; Vincristinum; Vincrstine; Vincrystine; Vinkristin; Indole alkaloid; Liposomal Vincristine; Onco TCS; Vincristina [DCIT]; Oncovin (TN); Tecnocris (TN); Vincristine (INN); Vincristine [INN:BAN]; Vincristinum [INN-Latin]; Lilly37231 (1:1 sulfate salt); Oncovin (1:1 sulfate salt); Vincasar (1:1 sulfate salt); Vincrex (1:1 sulfate salt); Vincaleukoblastine, 22-oxo-22-Oxovincaleukoblastine; Z-D-Val-Lys(Z)-OH; 22-Oxovincaleukoblastine
Click to Show/Hide
|
||||
Species Origin | Catharanthus roseus ... | Click to Show/Hide | |||
Catharanthus roseus | |||||
Disease | Leukaemia [ICD-11: 2A60-2B33] | Approved | [1] | ||
Structure |
Click to Download Mol2D MOL |
||||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
Formula |
C46H56N4O10
|
||||
PubChem CID | |||||
Canonical SMILES |
CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O
|
||||
InChI |
1S/C46H56N4O10/c1-7-42(55)22-28-23-45(40(53)58-5,36-30(14-18-48(24-28)25-42)29-12-9-10-13-33(29)47-36)32-20-31-34(21-35(32)57-4)50(26-51)38-44(31)16-19-49-17-11-15-43(8-2,37(44)49)39(60-27(3)52)46(38,56)41(54)59-6/h9-13,15,20-21,26,28,37-39,47,55-56H,7-8,14,16-19,22-25H2,1-6H3/t28-,37+,38-,39-,42+,43-,44-,45+,46+/m1/s1
|
||||
InChIKey |
OGWKCGZFUXNPDA-XQKSVPLYSA-N
|
||||
CAS Number |
CAS 57-22-7
|
||||
ChEBI ID | |||||
Herb ID | |||||
SymMap ID | |||||
TTD Drug ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
Sildenafil | Erectile dysfunction | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
|
Up-regulation | Cleavage | CASP8 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Expression | CCNB1 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Phosphorylation | CDK1 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
||
In-vitro Model | PC-3 | CVCL_0035 | Prostate carcinoma | Homo sapiens | ||
DU145 | CVCL_0105 | Prostate carcinoma | Homo sapiens | |||
Experimental
Result(s) |
Phosphodiesterase type 5 inhibitors synergize vincristine in killing castration-resistant prostate cancer through amplifying mitotic arrest signaling. | |||||
VE-465 | Hepatocellular carcinoma | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [3] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
|
Up-regulation | Cleavage | CASP7 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Cleavage | CASP9 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Phosphorylation | ERK1 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Phosphorylation | ERK2 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Phosphorylation | RAD53 | Molecule Info |
Pathway MAP
|
||
Biological
Regulation |
Induction | Cell cycle arrest in G2/M-phase | ||||
In-vitro Model | KCL-22 | CVCL_2091 | Chronic myelogenous leukemia | Homo sapiens | ||
K-562 | CVCL_0004 | Chronic myelogenous leukemia | Homo sapiens | |||
Ku812 | CVCL_0379 | Chronic myelogenous leukemia | Homo sapiens | |||
THP-1 | CVCL_0006 | Childhood acute monocytic leukemia | Homo sapiens | |||
HL-60 | CVCL_0002 | Adult acute myeloid leukemia | Homo sapiens | |||
U-937 | CVCL_0007 | Adult acute monocytic leukemia | Homo sapiens | |||
KY821 | CVCL_1346 | Acute myelomonocytic leukemia | Homo sapiens | |||
Experimental
Result(s) |
Vincristine potentiates the anti-proliferative effect of an aurora kinase inhibitor, VE-465, in myeloid leukemia cells. | |||||
Vorinostat | Mycosis fungoides | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [4] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
|
Down-regulation | Expression | BCL-xL | Molecule Info |
Pathway MAP
|
||
Up-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | HDAC6 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | MCL1 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Expression | PARP1 | Molecule Info |
Pathway MAP
|
||
Biological
Regulation |
Induction | Cell cycle arrest in G2/M phase | ||||
In-vitro Model | MOLT-4 | CVCL_0013 | Adult T acute lymphoblastic leukemia | Homo sapiens | ||
CCRF-CEM | CVCL_0207 | T acute lymphoblastic leukemia | Homo sapiens | |||
In-vivo Model | MOLT-4 cells were implanted (1*107 cells/ml) into severe combined immunodeficiency (SCID) mice. | |||||
Experimental
Result(s) |
The combination of vincristine and SAHA on T cell leukemic cells resulted in a change in microtubule dynamics contributing to M phase arrest followed by induction of the apoptotic pathway. | |||||
Tolfenamic acid | Pancreatic cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [5] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Expression | BIRC5 | Molecule Info |
Pathway MAP
|
|
Biological
Regulation |
Induction | Cell cycle arrest in G2/M phase | ||||
In-vitro Model | Daoy | CVCL_1167 | Medulloblastoma | Homo sapiens | ||
D283 Med | CVCL_1155 | Medulloblastoma | Homo sapiens | |||
Experimental
Result(s) |
Combination of clotam and vincristine enhances anti-proliferative effect in medulloblastoma cells. | |||||
Combretastatin A-4 phosphate | Rheumatoid arthritis | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [6] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Up-regulation | Expression | IL19 | Molecule Info |
Pathway MAP
|
|
Up-regulation | Expression | TNF | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | TRIM26 | Molecule Info | |||
In-vitro Model | Hep-G2 | CVCL_0027 | Hepatocellular carcinoma | Homo sapiens | ||
In-vivo Model | Rats received single I.P injection of Diethylnitrosamine (DENA) 200 mg/kg body weight, freshly dissolved in sterile 0.9% saline, as an inducer for hepatocellular carcinoma. | |||||
Experimental
Result(s) |
CA4-P showed a potential anti-cancer activity against hepatocellular carcinoma and this effect was greatly enhanced by co-administration with vincristine. | |||||
Belinostat | Solid tumour/cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [7] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Up-regulation | Expression | BCL2L11 | Molecule Info |
Pathway MAP
|
|
Down-regulation | Expression | MCL1 | Molecule Info |
Pathway MAP
|
||
In-vitro Model | SU-DHL-4 | CVCL_0539 | B-cell lymphoma | Homo sapiens | ||
DB | CVCL_1168 | B-cell lymphoma | Homo sapiens | |||
OCI-Ly19 | CVCL_1878 | B-cell lymphoma | Homo sapiens | |||
SU-DHL-8 | CVCL_2207 | B-cell lymphoma | Homo sapiens | |||
GM18564 | CVCL_P179 | Healthy | Homo sapiens | |||
Experimental
Result(s) |
Vincristine sensitizes DLBCL cells to the cytotoxic effects of belinostat. | |||||
Rituximab | Malignant haematopoietic neoplasm | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [8] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Biological
Regulation |
Increase | Tumor cell death | ||||
In-vitro Model | Ramos | CVCL_0597 | Burkitt lymphoma | Homo sapiens | ||
Experimental
Result(s) |
Rituximab synergizes with vincristine in the killing of Ramos Burkitt's lymphoma B cell line. | |||||
BI-D1870 | Mature B-cell leukaemia | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [9] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Biological
Regulation |
Induction | Cell cycle arrest in M phase | ||||
In-vitro Model | KG-1 | CVCL_0374 | Adult acute myeloid leukemia | Homo sapiens | ||
HL-60 | CVCL_0002 | Adult acute myeloid leukemia | Homo sapiens | |||
NALM-6 | CVCL_0092 | Adult B acute lymphoblastic leukemia | Homo sapiens | |||
Experimental
Result(s) |
BI-D1870 induces apoptosis of AML cells alone and in combination with vincristine through blocking mitotic exit, providing a novel approach to overcoming vincristine resistance in AML cells. | |||||
Volasertib | Acute myeloid leukaemia | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [10] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
In-vitro Model | A-204 | CVCL_1058 | Embryonal rhabdomyosarcoma | Homo sapiens | ||
RD | CVCL_1649 | Embryonal rhabdomyosarcoma | Homo sapiens | |||
Rh18 | CVCL_1659 | Alveolar rhabdomyosarcoma | Homo sapiens | |||
Rh30 | CVCL_0041 | Alveolar rhabdomyosarcoma | Homo sapiens | |||
Rh41 | CVCL_2176 | Alveolar rhabdomyosarcoma | Homo sapiens | |||
RMS-1 | CVCL_UF94 | Embryonal rhabdomyosarcoma | Homo sapiens | |||
RMS-YM | CVCL_A792 | Embryonal rhabdomyosarcoma | Homo sapiens | |||
Experimental
Result(s) |
Volasertib exhibits antitumor activity and synergy with vincristine in alveolar rhabdomyosarcoma. | |||||
Dipyridamole | Hypertension | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [11] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
In-vitro Model | MOLT-3 | CVCL_0624 | Adult T acute lymphoblastic leukemia | Homo sapiens | ||
ML1 | CVCL_0436 | Adult acute myeloid leukemia | Homo sapiens | |||
BL-TH | Burkitt's lymphoma | Homo sapiens | ||||
Experimental
Result(s) |
Dipyridamole and vincristine combination showed synergistic inhibitory effects on the growth of human leukaemia and lymphoma cell lines. | |||||
Methotrexate | Leukaemia | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [12] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
In-vitro Model | MOLT-3 | CVCL_0624 | Adult T acute lymphoblastic leukemia | Homo sapiens | ||
Experimental
Result(s) |
Simultaneous exposure of VCR and MTX produced subadditive or mutually protective interactions. | |||||
Topotecan | Ovarian cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [13] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
In-vitro Model | Rh18 | CVCL_1659 | Alveolar rhabdomyosarcoma | Homo sapiens | ||
D283 Med | CVCL_1155 | Medulloblastoma | Homo sapiens | |||
Daoy | CVCL_1167 | Medulloblastoma | Homo sapiens | |||
SJ-GBM2 | CVCL_M141 | Glioblastoma | Homo sapiens | |||
NB-EB | Neuroblastoma | Homo sapiens | ||||
RMSs | Embryonal rhabdomyosarcoma | Homo sapiens | ||||
Experimental
Result(s) |
The therapeutic effect of combining topotecan with vincristine was greater than additive in most tumor models of childhood solid tumors tested. |
Target and Pathway | ||||
---|---|---|---|---|
Target(s) | Tubulin beta (TUBB) | Molecule Info | [14] | |
KEGG Pathway | Phagosome | Click to Show/Hide | ||
2 | Gap junction | |||
3 | Pathogenic Escherichia coli infection | |||
NetPath Pathway | FSH Signaling Pathway | Click to Show/Hide | ||
2 | TCR Signaling Pathway | |||
3 | EGFR1 Signaling Pathway | |||
Panther Pathway | Cytoskeletal regulation by Rho GTPase | Click to Show/Hide | ||
2 | Huntington disease | |||
Reactome | Regulation of PLK1 Activity at G2/M Transition | Click to Show/Hide | ||
2 | Loss of Nlp from mitotic centrosomes | |||
3 | Recruitment of mitotic centrosome proteins and complexes | |||
4 | Loss of proteins required for interphase microtubule organization?from the centrosome | |||
5 | Anchoring of the basal body to the plasma membrane | |||
WikiPathways | Parkin-Ubiquitin Proteasomal System pathway | Click to Show/Hide | ||
2 | Pathogenic Escherichia coli infection | |||
3 | Mitotic G2-G2/M phases |